Valeant may seek to clean up its name by changing it: Reuters
Valeant Pharmaceuticals International Plc, the drugmaker that became a poster child for high drug prices during the U.S. election season, may change its name to help boost its reputation, Reuters reported, citing comments made by U.S. hedge fund investor William Ackman. A name change would be the latest effort by the company to break from its past, after hiring a new chief executive, overhauling the board, and exploring billions of dollars in asset sales to pay down a US$30 billion debt load.
11 November 2016•2 mins read
